£1.7 Million Investment for UK Developers of World’s First Portable Fingerprint Drug Test
UK-based Intelligent Fingerprinting, developers of the world’s first portable fingerprint drug test, have secured a further £1.7 million of funding from a group of private US and UK investors. The investment will help accelerate commercialisation of the recently launched Intelligent Fingerprinting Drug Screening System – particularly into key UK workplace market sectors such as construction, transport, warehousing and manufacturing.
Intelligent Fingerprinting develops and manufactures its drug screening system from a dedicated facility in Cambridge. Commenting on this latest investment, the company’s Chairman, Philip Hand said: “Following the successful launch of our fingerprint drug test, and our transition from successful pilot projects to commercial engagements, we’re now focused on strengthening our UK sales and marketing resources as well as our international offering. This latest funding will see the company place increased emphasis on the critical workplace sector, and will also help support our ongoing FDA approval activities in the USA.”
The unique Intelligent Fingerprinting Drug Screening System works by analysing the sweat from a fingerprint, so – unlike traditional urine or saliva-based drug testing – it’s non-invasive, fast and cost-effective. By collecting and analysing tiny traces of sweat from a fingerprint, the Intelligent Fingerprinting test can detect drugs and drug metabolites in under 10 minutes. The system features a single-use cartridge that screens for multiple drug groups simultaneously (currently amphetamines, cannabis, cocaine and opiates), with sample collection taking just 5 seconds.
Since its commercial launch in August 2017, the fingerprint drug test has quickly proved itself, and is already in use in the UK across a range of applications including for screening in the workplace; supporting drug recovery programmes; and to help with coroner investigations in mortuaries.
Intelligent Fingerprinting secured initial seed investment in 2009, followed by the first round of funding from the company’s US investors in 2012. Prior to today’s announcement, the company has raised over £11 million of private investment over the past six years – in addition to its original funding of £0.5 million.
This article has been republished from materials provided by Intelligent Fingerprinting. Note: material may have been edited for length and content. For further information, please contact the cited source.
Chronic Wasting Disease Didn't Cross Into PrimatesNews
Chronic wasting disease did not cross the species barrier to infect cynomolgus macaque monkeys during a lengthy investigation exploring risks to humans.READ MORE
Feisty Fetal T Cells Can Rebel In UteroNews
Preterm labor, a common pregnancy complication, has long been a mystery to scientists. But a new study shows it may sometimes happen when the fetal immune system “wakes up” too early and begins to reject the mother, causing the uterus to start contracting.READ MORE
Sun Not Only Detrimental To SkinNews
Chemical dispersants are one of the tools that can help mitigate the impact of oil spills, but they become less effective as oil weathers in the environment. Now, one group reports that sunlight has a much greater impact than previously thought on the effectiveness of these dispersants.